Small fiber neuropathy associated with SARS-CoV-2 infection.
SARS-CoV-2
long-haul COVID-19 symptoms
neurological complications
post-acute COVID-19 syndrome
small fiber neuropathy
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
02
11
2021
received:
01
06
2021
accepted:
07
11
2021
pubmed:
13
11
2021
medline:
29
3
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
The development and persistence of neurological symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is referred to as "long-haul" syndrome. We aimed to determine whether small fiber neuropathy (SFN) was associated with SARS-CoV-2 infection. We retrospectively studied the clinical features and outcomes of patients who were referred to us between May 2020 and May 2021 for painful paresthesia and numbness that developed during or after SARS-CoV-2 infection and who had nerve conduction studies showing no evidence of a large fiber polyneuropathy. We identified 13 patients, Eight women and five men with age ranging from 38-67 y. Follow-up duration ranged from 8 to 12 mo. All patients developed new-onset paresthesias within 2 mo following SARS-CoV-2 infection, with an acute onset in seven and co-existing autonomic symptoms in seven. Three patients had pre-existing but controlled neuropathy risk factors. Skin biopsy confirmed SFN in six, all of whom showed both neuropathy symptoms and signs, and two also showed autonomic dysfunction by autonomic function testing (AFT). Of the remaining seven patients who had normal skin biopsies, six showed no clinical neuropathy signs and one exhibited signs and had abnormal AFT. Two patients with markedly reduced intraepidermal nerve fiber densities and one with normal skin biopsy had severe and moderate coronavirus disease 2019 (COVID-19); the remainder experienced mild COVID-19 symptoms. Nine patients received symptomatic neuropathy treatment with paresthesias controlled in seven (77.8%). Our findings suggest that symptoms of SFN may develop during or shortly after COVID-19. SFN may underlie the paresthesias associated with long-haul post-COVID-19 symptoms.
Identifiants
pubmed: 34766365
doi: 10.1002/mus.27458
pmc: PMC8661991
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440-443Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Eur J Neurol. 2010 Jul;17(7):903-12, e44-9
pubmed: 20642627
Muscle Nerve. 2022 Apr;65(4):440-443
pubmed: 34766365
eNeurologicalSci. 2020 Dec;21:100276
pubmed: 32984564
Clin Auton Res. 2021 Jun;31(3):385-394
pubmed: 33860871
Immunol Res. 2021 Apr;69(2):205-211
pubmed: 33786700
Muscle Nerve. 2012 Jan;45(1):86-91
pubmed: 22190313
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):163-9
pubmed: 17911181
Neurology. 2020 Sep 29;95(13):559-560
pubmed: 32788251